一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括Bevacizumab (Bev)；Trastuzumab Deruxtecan (T-DXd)，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Bevacizumab (Bev)；Trastuzumab Deruxtecan (T-DXd) · II 期
登记条件中文摘要
登记的基本范围为女性，年龄18 岁至70 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Center · 上海
公开的入选条件
- 1. ECOG score of 0 to 1.
- 2. Expected survival period greater than 12 weeks.
- 3. Histologically confirmed invasive HER2-low expressing breast cancer (specific definition: breast cancer patients with low expression of human epidermal growth factor receptor 2 (HER-2) as determined by pathological testing. Specifically: HER2 IHC 1+ or HER2
- 4. Tumor stage: recurrent or metastatic breast cancer; local recurrence must be confirmed by the researcher to be unable to undergo radical surgical resection.
- 5. Patients must have at least one lesion that has not previously received radiation therapy (measurable and/or non-measurable).
- 6. MRI or CT shows brain metastasis and meets one of the following conditions:
- i) Untreated brain parenchymal metastasis found by imaging screening; ii) Previously locally treated stable or progressive brain parenchymal metastasis and meets one of the following conditions:a) Imaging stability ≥4 weeks; b) New brain parenchymal metastasis
- 7. Received no more than 2 lines of chemotherapy after metastasis.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07150208；登记信息更新于 2026-09-25。